The nation of Zimbabwe has declined a significant US health deal valued at 367 million US dollars (£272m) over five years over the United States' request for confidential information.
The decision came to light after a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "unbalanced".
A government spokesperson later explained that the US was requesting health data for research and commercial purposes but was not willing to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more dialogue to reach a agreement agreeable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Background
This development comes after a similar situation in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were raised about the security of Kenyans' health data.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
According to statements, Sixteen African countries have so far signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, with no corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our population should a new disease outbreak emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending frameworks already set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This mechanism is intended to ensure that when a country provides its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing dialogue with our American counterparts on how future co-operation could be designed in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts stated it understood the official position, but recommended that talks must proceed given that a large portion of the nation's HIV programmes were funded by international support.
"Where specific concerns exist, such as those relating to information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," it said.
This impasse underscores the complex debate between receiving crucial international aid and protecting a country's data in an increasingly data-driven world.